Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 55

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 55
---
, which occurs when the eye’s lens focuses images in front of the retina ra ther than on the retinal surface. A person with myopia cannot clearly see distant objects without eyeglasses or contact lenses Myopia Of or related to the eye Ophthalmic A clear, artificial lens that is placed inside the eye to correct vision Phakic intraocular lens The first type of laser surgical operation to correct nearsightedness, farsightedness, or astigmatism Photorefractive keratectomy (PRK) The overall volume of refractive surgical procedures of all kinds, including LASIK, PRK, RLE, the ICL product family and othe r p hakic IOLs Refractive market A type of surgery that aims to correct refractive errors – astigmatism, hyperopia and myopia Refractive surgery A newer type of refractive surgery used to correct astigmatism and hyperopia during which a small, disc - shaped piece of corneal tissue (lenticule) is created inside the cornea and then manually dissected and removed, resulting in a reshaped cornea Small incision lenticule extraction (SMILE) Refers to the shape of a lens designed to correct astigmatism, which has greater refractive power in some sections of the len s t han others Toric

CONFIDENTIAL © All rights reserved. Two Seas Capital LP INVESTOR PRESENTATION APPENDIX D: Important Information 06

Broadwood Partners, L.P. Important Information 79 CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Broadwood Partners, Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn , Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the “Participants”) have filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Definitive Proxy Statem ent ”) and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of STAAR Surgical Company (the “Company”) for the special m eet ing of stockholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special Meeting”). STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTIC